Kardia Therapeutics Overview
- Founded
-
2002
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Kardia Therapeutics General Information
Description
Developer of a research-stage biotechnology platform designed to focus on the development of cardiac regenerative treatments. The company's platform emphasizes in the areas of myocardial infarction and heart failure by using a three-way related approaches namely, Adult Cardiac Progenitor Cell Therapy, Stem Cell Optimization Technologies and Homing-Growth Factor Therapies, enabling physicians to avail significantly improved health outcomes compared to existing treatments.
Contact Information
Website
www.kardiatherapeutics.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Primary Office
- 1709 Dryden Road
- Suite 910
- Houston, TX 77030
- United States
+1 (713) 000-0000
Kardia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 01-Oct-2018 | Completed | Out of Business | |||
| 4. Early Stage VC | Completed | Startup | ||||
| 3. Grant | 01-Jan-2007 | 00.000 | Completed | Startup | ||
| 2. Grant | 01-Jan-2005 | $526K | Completed | Startup | ||
| 1. Grant | 01-Jan-2004 | $100K | Completed | Startup |
Kardia Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kardia Therapeutics Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Royal Brompton | Founder & Scientific Board Member |
Kardia Therapeutics Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Royal Brompton | Kardia Therapeutics | Founder & Scientific Board Member | 000 0000 |